Jim Chilcott

All publications

Journal articles

• Mandrik O, Thomas C & Chilcott J (2024) Development of the Microsimulation Model in Cancers of Bladder and Kidney (MiMiC-BlaKy). HEDS Discussion Paper Series(24.03). View this article in WRRO
• Kar D, El-Wazir A, Nath M, Breeze P, Jetha K, Strong M, Chilcott J, Davies MJ, Lee A, Lusignan SD , Khunti K et al (2023) Relationship of cardiorenal risk factors with albuminuria based on age, smoking, glycaemic status and BMI: a retrospective cohort study of the UK Biobank data. BMJ Public Health, 1(1). View this article in WRRO
• Hock ES, Franklin M, Baxter S, Clowes M, Chilcott J & Gillespie D (2023) Covariates of success in quitting smoking: a systematic review of studies from 2008 to 2021 conducted to inform the statistical analyses of quitting outcomes of a hospital-based tobacco dependence treatment service in the United Kingdom. NIHR Open Research, 3(28). View this article in WRRO
• Catto JWF, North B, Goff M, Carter A, Sleeth M, Mandrik O, Chilcott J, Sasieni P & Cumberbatch MGK (2023) Protocol for the YORKSURe prospective multistage study testing the feasibility for early detection of bladder cancer in populations with high disease-specific mortality risk. BMJ Open, 13(9), e076612-e076612.
• Mandrik O, Hahn AI, Catto JWF, Zauber AG, Cumberbatch M & Chilcott J (2023) Critical appraisal of decision models used for the economic evaluation of bladder cancer screening and diagnosis: a systematic review. PharmacoEconomics.
• Catto JWF, Mandrik O, Quayle LA, Hussain SA, McGrath J, Cresswell J, Birtle AJ, Jones RJ, Mariappan P, Makaroff LE , Knight A et al (2023) Diagnosis, treatment and survival from bladder, upper urinary tract and urethral cancers: Real world findings from NHS England between 2013 and 2019. BJU International.
• Mahdi S, Chilcott J & Buckland NJ (2022) Evaluating the Change4Life Food Scanner app in reducing children's sugar intake: a randomised pilot and feasibility study.. Lancet, 400 Suppl 1, S13.
• Mahdi S, Chilcott J & Buckland NJ (2022) Evaluating the Change4Life Food Scanner app in reducing children's sugar intake: a randomised pilot and feasibility study. The Lancet, 400, S13-S13.
• Mandrik O, Chilcott J & Thomas C (2022) Modelling the impact of the coronavirus pandemic on bowel cancer screening outcomes in England: a decision analysis to prepare for future screening disruption. Preventive Medicine, 160. View this article in WRRO
• Mandrik O, Thomas C, Whyte S & Chilcott J (2022) Calibrating natural history of cancer models in the presence in the presence of data incompatibility; problems and solutions. PharmacoEconomics. View this article in WRRO
• Mahdi S, Marr C, Buckland NJ & Chilcott J (2022) Methods for the economic evaluation of obesity prevention dietary interventions in children: A systematic review and critical appraisal of the evidence. Obesity Reviews.
• Tong T, Aber A, Chilcott J, Thokala P, Walters SJ, Maheswaran R, Nawaz S, Thomas S & Michaels J (2021) Volume–outcome relationships in open and endovascular repair of abdominal aortic aneurysm: administrative data 2006–2018. British Journal of Surgery, 108(5), 521-527. View this article in WRRO
• Whyte S, Thomas C, Chilcott J & Kearns B (2021) Optimizing the Design of a Repeated Fecal Immunochemical Test Bowel Cancer Screening Programme With a Limited Endoscopy Capacity From a Health Economic Perspective. Value in Health.
• Romero CP, Marinho DS, Castro R, de Aguiar Pereira CC, Silva E, Caetano R, Silva Elias FT, Chilcott J & Dixon S (2020) Cost-Effectiveness Analysis of Point-of-Care Rapid Testing Versus Laboratory-Based Testing for Antenatal Screening of Syphilis in Brazil. Value in Health Regional Issues, 23, 61-69.
• Bessey A, Chilcott J, Pandor A & Paisley S (2020) The cost-effectiveness of expanding the UK newborn bloodspot screening programme to include five additional inborn errors of metabolism. International Journal of Neonatal Screening, 6(4). View this article in WRRO
• Moat SJ, Dibden C, Tetlow L, Griffith C, Chilcott J, George R, Hamilton L, Wu THY, MacKenzie F & Hall SK (2020) Effect of blood volume on analytical bias in dried blood spots prepared for newborn screening external quality assurance. Bioanalysis, 12(2), 99-109.
• Aber A, Tong T, Chilcott J, Maheswaran R, Thomas SM, Nawaz S & Michaels J (2019) Outcomes of aortic aneurysm surgery in England : a nationwide cohort study using hospital admissions data from 2002 to 2015. BMC Health Services Research, 19(1). View this article in WRRO
• Bessey A, Chilcott J, Leaviss J, de la Cruz C & Wong R (2019) A cost-effectiveness analysis of newborn screening for severe combined immunodeficiency in the UK. International Journal of Neonatal Screening, 5(3). View this article in WRRO
• Thomas C, Whyte S, Kearns B & Chilcott JB (2019) External Validation of a Colorectal Cancer Model Against Screening Trial Long-Term Follow-Up Data. Value in Health, 22(10), 1154-1161. View this article in WRRO
• Aber A, Tong T, Chilcott J, Maheswaran R, Thomas SM, Nawaz S & Michaels J (2018) Gender Differences in the Rates of Repair of Emergency Abdominal Aortic Aneurysm. European Journal of Vascular and Endovascular Surgery, 56(6), e30-e30.
• Aber A, Tong TS, Chilcott J, Thokala P, Maheswaran R, Thomas SM, Nawaz S, Walters S & Michaels J (2018) Sex differences in national rates of repair of emergency abdominal aortic aneurysm. British Journal of Surgery. View this article in WRRO
• Bessey A, Chilcott JB, Leaviss J & Sutton A (2018) Economic impact of screening for X-linked Adrenoleukodystrophy within a newborn blood spot screening programme.. Orphanet J Rare Dis, 13(1), 179-179. View this article in WRRO
• Kearns B, Chilcott J, Relton C, Whyte S, Woods HB, Nickerson C & Loban A (2018) The association between long-term conditions and uptake of population-based screening for colorectal cancer: results from two English cohort studies. Cancer Management and Research, 10, 637-645. View this article in WRRO
• Burns J, Polus S, Brereton L, Chilcott J, Ward SE, Pfadenhauer LM & Rehfuess EA (2017) Looking beyond the forest: Using harvest plots, gap analysis, and expert consultations to assess effectiveness, engage stakeholders, and inform policy. Research Synthesis Methods. View this article in WRRO
• Brereton L, Wahlster P, Mozygemba K, Lysdahl K, Burns J, Polus S, Tummers M, Refolo P, Sacchini D, Leppert W , Chilcott J et al (2017) Stakeholder involvement throughout health technology assessment: an example from palliative care. International Journal of Technology Assessment in Health Care, 33(5), 552-561. View this article in WRRO
• Sadler S, Tosh J, Pennington R, Rawdin A, Squires H, Romero C, Fischer A & Chilcott J (2017) A cost-effectiveness analysis of condom distribution programmes for the prevention of sexually transmitted infections in England.. Journal of Epidemiology and Community Health, 71, 897-904. View this article in WRRO
• Lysdahl KB, Mozygemba K, Burns J, Brönneke JB, Chilcott JB, Ward S & Hofmann B (2017) Comprehensive assessment of complex technologies: integrating various aspects in health technology assessment. International Journal of Technology Assessment in Health Care, 33(5), 570-576. View this article in WRRO
• Breeze PR, Thomas C, Squires H, Brennan A, Greaves C, Diggle P, Brunner E, Tabak A, Preston L & Chilcott J (2017) Cost‐effectiveness of population‐based, community, workplace and individual policies for diabetes prevention in the UK. Diabetic Medicine, 34(8), 1136-1144. View this article in WRRO
• Breeze PR, Thomas C, Squires H, Brennan A, Greaves C, Diggle PJ, Brunner E, Tabak A, Preston L & Chilcott J (2017) The impact of Type 2 diabetes prevention programmes based on risk‐identification and lifestyle intervention intensity strategies: a cost‐effectiveness analysis. Diabetic Medicine, 34(5), 632-640. View this article in WRRO
• Brereton L, Ingleton C, Gardiner C, Goyder E, Mozygemba K, Lysdahl KB, Tummers M, Sacchini D, Leppert W, Blazeviciene A , van der Wilt GJ et al (2017) Lay and professional stakeholder involvement in scoping palliative care issues: Methods used in seven European countries. Palliative Medicine, 31(2), 181-192. View this article in WRRO
• Kearns B, Chilcott J, Whyte S, Preston L & Sadler S (2016) Cost-effectiveness of screening for ovarian cancer amongst postmenopausal women: a model-based economic evaluation. BMC Medicine, 14(1), 200-200. View this article in WRRO
• Breeze P, Squires H, Chilcott J, Stride C, Diggle PJ, Brunner E, Tabak A & Brennan A (2016) A statistical model to describe longitudinal and correlated metabolic risk factors: the Whitehall II prospective study.. J Public Health (Oxf), 38(4), 679-687. View this article in WRRO
• McNamee P, Murray E, Kelly MP, Bojke L, Chilcott J, Fischer A, West R & Yardley L (2016) Designing and Undertaking a Health Economics Study of Digital Health Interventions. American Journal of Preventive Medicine, 51(5), 852-860. View this article in WRRO
• Squires H, Chilcott J, Akehurst R, Burr J & Kelly MP (2016) A Framework for Developing the Structure of Public Health Economic Models. Value in Health, 19(5), 588-601. View this article in WRRO
• Squires H, Chilcott J, Akehurst R, Burr J & Kelly MP (2016) A systematic literature review of the key challenges for developing the structure of public health economic models. International Journal of Public Health, 61(3), 289-298. View this article in WRRO
• Kearns B, Whyte S, Seaman HE, Snowball J, Halloran SP, Butler P, Patnick J, Nickerson C & Chilcott J (2016) Factors associated with completion of bowel cancer screening and the potential effects of simplifying the screening test algorithm. British Journal of Cancer, 114(3), 327-333. View this article in WRRO
• (2016) Retracted:Impact of Type 2 diabetes prevention programmes based on risk identification and lifestyle intervention intensity strategies: a cost-effectiveness analysis. Diabetic Medicine, 33(8), 1155-1163.
• Tappenden P & Chilcott J (2014) Avoiding and Identifying Errors and Other Threats To the Credibility of Health Economic Models. Value in Health, 17(7), A585-A585.
• Kearns B, Whyte S, Chilcott J & Patnick J (2014) Guaiac faecal occult blood test performance at initial and repeat screens in the English Bowel Cancer Screening Programme. British Journal of Cancer, 111(9), 1734-1741. View this article in WRRO
• Tappenden P & Chilcott JB (2014) Avoiding and identifying errors and other threats to the credibility of health economic models.. Pharmacoeconomics, 32(10), 967-979.
• Watson P, Preston L, Squires H, Chilcott J & Brennan A (2014) Modelling the economics of type 2 diabetes mellitus prevention: a literature review of methods.. Appl Health Econ Health Policy, 12(3), 239-253.
• Rawdin AC, Duenas A & Chilcott JB (2014) The cost-effectiveness of weight management programmes in a postnatal population. Public Health, 128(9), 804-810.
• Everson-Hock ES, Johnson M, Jones R, Woods HB, Goyder E, Payne N & Chilcott J (2013) Community-based dietary and physical activity interventions in low socioeconomic groups in the UK: A mixed methods systematic review. Preventive Medicine, 56(5), 265-272. View this article in WRRO
• Sharp L, Tilson L, Whyte S, Ceilleachair AO, Walsh C, Usher C, Tappenden P, Chilcott J, Staines A, Barry M & Comber H (2013) Using resource modelling to inform decision making and service planning: the case of colorectal cancer screening in Ireland.. BMC Health Serv Res, 13, 105. View this article in WRRO
• Tappenden P, Chilcott J, Brennan A, Squires H, Glynne-Jones R & Tappenden J (2013) Using Whole Disease Modeling to Inform Resource Allocation Decisions: Economic Evaluation of a Clinical Guideline for Colorectal Cancer Using a Single Model. Value in Health.
• Pollock RF, Chilcott J, Muduma G & Valentine WJ (2013) Laparoscopic adjustable gastric banding vs standard medical management in obese patients with type 2 diabetes: a budget impact analysis in the UK.. J Med Econ, 16(2), 249-259.
• Tappenden P, Chilcott J, Brennan A, Squires H & Stevenson M (2012) Whole disease modeling to inform resource allocation decisions in cancer: a methodological framework.. Value Health, 15(8), 1127-1136.
• Squires H, Chilcott J, Akehurst R & Burr J (2012) Guidance for modellers for developing public health economic models. The Lancet, 380, S68-S68.
• Whyte S, Chilcott J & Halloran S (2012) Reappraisal of the options for colorectal cancer screening in England.. Colorectal Dis, 14(9), e547-e561.
• Sharp L, Tilson L, Whyte S, O'Ceilleachair A, Walsh C, Usher C, Tappenden P, Chilcott J, Staines A, Barry M & Comber H (2012) Cost-effectiveness of population-based screening for colorectal cancer: a comparison of guaiac-based faecal occult blood testing, faecal immunochemical testing and flexible sigmoidoscopy.. Br J Cancer, 106(5), 805-816. View this article in WRRO
• Everson-Hock ES, Jones R, Guillaume L, Clapton J, Goyder E, Chilcott J, Payne N, Duenas A, Sheppard LM & Swann C (2012) The effectiveness of training and support for carers and other professionals on the physical and emotional health and well-being of looked-after children and young people: A systematic review. Child: Care, Health and Development, 38(2), 162-174.
• Tilson L, Sharp L, Usher C, Walsh C, Whyte S, O'Ceilleachair A, Stuart C, Mehigan B, Kennedy MJ, Tappenden P , Chilcott J et al (2012) Cost of care for colorectal cancer in Ireland: A health care payer perspective. European Journal of Health Economics, 13(4), 511-524.
• Everson-Hock ES, Jones R, Guillaume L, Clapton J, Duenas A, Goyder E, Chilcott J, Cooke J, Payne N, Sheppard LM & Swann C (2011) Supporting the transition of looked-after young people to independent living: a systematic review of interventions and adult outcomes.. Child Care Health Dev, 37(6), 767-779.
• Strong M, Oakley JE & Chilcott J (2011) Managing structural uncertainty in health economic decision models: A discrepancy approach. Journal of the Royal Statistical Society. Series C: Applied Statistics. View this article in WRRO
• Jones R, Everson-Hock ES, Papaioannou D, Guillaume L, Goyder E, Chilcott J, Cooke J, Payne N, Duenas A, Sheppard LM & Swann C (2011) Factors associated with outcomes for looked-after children and young people: a correlates review of the literature.. Child Care Health Dev, 37(5), 613-622. View this article in WRRO
• Whyte S, Walsh C & Chilcott J (2011) Bayesian Calibration of a Natural History Model with Application to a Population Model for Colorectal Cancer. Medical Decision Making, 31(4), 625-641.
• Bending MW, Trueman P, Lowson KV, Pilgrim H, Tappenden P, Chilcott J & Tappenden J (2010) Estimating the direct costs of bowel cancer services provided by the National Health Service in England.. Int J Technol Assess Health Care, 26(4), 362-369.
• Chilcott J, Tappenden P, Rawdin A, Johnson M, Kaltenthaler E, Paisley S, Papaioannou D & Shippam A (2010) Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.. Health Technol Assess, 14(25), iii-107.
• Oakley JE, Brennan A, Tappenden P & Chilcott J (2010) Simulation sample sizes for Monte Carlo partial EVPI calculations.. J Health Econ, 29(3), 468-477. View this article in WRRO
• Blank L, Baxter S, Naylor PB, Guillaume L, Wilkinson A, Hummel S, Chilcott J & Goyder E (2010) Promoting wellbeing by changing behaviour; a systematic review and narrative synthesis of the effectiveness of whole secondary school behavioural interventions.. Mental Health Review Journal, 2(15), 43-53.
• Bending MW, Trueman P, Lowson KV, Pilgrim H, Tappenden P, Chilcott J & Tappenden J (2010) Estimating the direct costs of bowel cancer services provided by the National Health Service in England. International Journal of Technology Assessment in Health Care, 26(4), 362-369.
• McCabe C, Chilcott J, Claxton K, Tappenden P, Cooper C, Roberts J, Cooper N & Abrams K (2010) Continuing the multiple sclerosis risk sharing scheme is unjustified.. BMJ, 340, c1786.
• Pilgrim H, Tappenden P, Chilcott J, Bending M, Trueman P, Shorthouse A & Tappenden J (2009) The costs and benefits of bowel cancer service developments using discrete event simulation. J OPER RES SOC, 60(10), 1305-1314.
• Sharp L, Tilson L, Whyte S, O'Ceilleachair A, Walsh C, Usher C, Tappenden P, Chilcott J, Staines A, Comber H & Barry M (2009) COST-EFFECTIVENESS OF A POPULATION-BASED COLORECTAL CANCER SCREENING PROGRAMME IN IRELAND. VALUE HEALTH, 12(7), A280-A280.
• Tappenden P, Chilcott J, Brennan A & Pilgrim H (2009) Systematic review of economic evidence for the detection, diagnosis, treatment, and follow-up of colorectal cancer in the United Kingdom.. Int J Technol Assess Health Care, 25(4), 470-478.
• Whyte S, Walsh C, Sharp L, O'Ceilleachair A, Tilson L, Usher C, Chilcott J, Tappenden P, Staines A, Comber H & Barry M (2009) PMC46 BAYESIAN CALIBRATION OF A NATURAL HISTORY MODEL FOR COLORECTAL CANCER. Value in Health, 12(7), A395-A395.
• Chilcott J, Lloyd Jones M & Wilkinson A (2009) Docetaxel for the adjuvant treatment of early node-positive breast cancer: a single technology appraisal.. Health Technol Assess, 13 Suppl 1, 7-13.
• Pandor A, Ara RM, Tumur I, Wilkinson AJ, Paisley S, Duenas A, Durrington PN & Chilcott J (2009) Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials.. J Intern Med, 265(5), 568-580.
• Simpson EL, Duenas A, Holmes MW, Papaioannou D & Chilcott J (2009) Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin: systematic review and economic evaluation.. Health Technol Assess, 13(17), iii-154.
• Tappenden P, McCabe C, Chilcott J, Simpson E, Nixon R, Madan J, Fisk JD & Brown M (2009) Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population.. Value Health, 12(5), 657-665.
• Kerner JF, Cazap E, Yach D, Pierotti MA, Daidone MG, De Blasio P, Geary P, Schacter B, Sant M, Habbema JDF , Sankaranarayanan R et al (2009) Comprehensive cancer control-research & development: Knowing what we do and doing what we know. Tumori, 95(5), 610-622.
• Pickin M, Cooper CL, Chater T, O'Hagan A, Abrams KR, Cooper NJ, Boggild M, Palace J, Ebers G, Chilcott JB , Tappenden P et al (2009) The Multiple Sclerosis Risk Sharing Scheme Monitoring Study--early results and lessons for the future.. BMC Neurol, 9, 1. View this article in WRRO
• Wailoo A, Bansback N & Chilcott J (2008) Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance: reply. RHEUMATOLOGY, 47(10), 1590-1590.
• Ara R, Pandor A, Tumur I, Paisley S, Duenas A, Williams R, Wilkinson A, Durrington P & Chilcott J (2008) Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registries.. Clin Ther, 30(8), 1508-1523.
• Pilgrim H & Chilcott J (2008) Assessment of a 7-day turn-around for the reporting of cervical smear results using discrete event simulation. J OPER RES SOC, 59(7), 902-910.
• Dixon S, Faghih Nasiri F, Ledger WL, Lenton EA, Duenas A, Sutcliffe P & Chilcott JB (2008) Cost-effectiveness analysis of different embryo transfer strategies in England.. BJOG, 115(6), 758-766.
• Wailoo A, Bansback N & Chilcott J (2008) Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance.. Rheumatology (Oxford), 47(2), 119-120.
• Ara R, Tumur I, Pandor A, Duenas A, Williams R, Wilkinson A, Paisley S & Chilcott J (2008) Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation.. Health Technol Assess, 12(21), iii-212.
• Ara R, Pandor A, Tumur I, Paisley S, Duenas A, Williams R, Rees A, Wilkinson A, Durrington P & Chilcott J (2008) Cost effectiveness of ezetimibe in patients with cardiovascular disease and statin intolerance or contraindications: a Markov model.. Am J Cardiovasc Drugs, 8(6), 419-427.
• Garthwaite PH, Chilcott JB, Jenkinson DJ & Tappenden P (2008) Use of expert knowledge in evaluating costs and benefits of alternative service provisions: a case study.. Int J Technol Assess Health Care, 24(3), 350-357.
• Brennan A, Kharroubi S, O'hagan A & Chilcott J (2007) Calculating partial expected value of perfect information via Monte Carlo sampling algorithms.. Med Decis Making, 27(4), 448-470.
• Tappenden P, Chilcott J, Eggington S, Patnick J, Sakai H & Karnon J (2007) Option appraisal of population-based colorectal cancer screening programmes in England.. Gut, 56(5), 677-684.
• Chilcott J (2007) Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis (vol 326, pg 522, 2003). BRIT MED J, 334(7595), 685-685.
• Chilcott J (2007) Erratum: Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis (British Medical Journal (2003) 326, (522-525) DOI: 10.1136/bmj.326.7388.522). British Medical Journal, 334(7595), 685.
• Tappenden P, Brazier J, Ratcliffe J & Chilcott J (2007) A stated preference binary choice experiment to explore NICE decision making.. Pharmacoeconomics, 25(8), 685-693.
• Eggington S, Tappenden P, Pandor A, Paisley S, Saunders M, Seymour M, Sutcliffe P & Chilcott J (2006) Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer.. Br J Cancer, 95(9), 1195-1201. View this article in WRRO
• Tappenden P, Chilcott J, Ward S, Eggington S, Hind D & Hummel S (2006) Methodological issues in the economic analysis of cancer treatments.. Eur J Cancer, 42(17), 2867-2875.
• Mar J, Gutiérrez-Moreno S & Chilcott J (2006) [Probabilistic cost-effectiveness analysis of the treatment of sleep apnea].. Gac Sanit, 20(1), 47-53.
• Vergel YB, Chilcott J, Kaltenthaler E, Walters S, Blakeborough A & Thomas S (2006) Economic evaluation of MR cholangiopancreatography compared to diagnostic ERCP for the investigation of biliary tree obstruction. International Journal of Surgery, 4(1), 12-19.
• Pandor A, Eastham J, Chilcott J, Paisley S & Beverley C (2006) Economics of tandem mass spectrometry screening of neonatal inherited disorders.. Int J Technol Assess Health Care, 22(3), 321-326. View this article in WRRO
• Kaltenthaler EC, Walters SJ, Chilcott J, Blakeborough A, Vergel YB & Thomas S (2006) MRCP compared to diagnostic ERCP for diagnosis when biliary obstruction is suspected: a systematic review.. BMC Med Imaging, 6, 9. View this article in WRRO
• Warren E, Weatherley-Jones E, Chilcott J & Beverley C (2004) Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Health technology assessment (Winchester, England), 8(45).
• Warren E, Weatherly-Jones E, Chilcott J & Beverley C (2004) Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. HEALTH TECHNOL ASSES, 8(45), 1-+. View this article in WRRO
• Warren E, Weatherley-Jones E, Chilcott J & Beverley C (2004) Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine.. Health Technol Assess, 8(45), iii-57.
• Chilcott J, Tappenden P, Lloyd Jones M, Wight J, Forman K, Wray J & Beverley C (2004) The economics of routine antenatal anti-D prophylaxis for pregnant women who are rhesus negative.. BJOG, 111(9), 903-907.
• Jones ML, Wray J, Wight J, Chilcott J, Forman K, Tappenden P & Beverley C (2004) A review of the clinical effectiveness of routine antenatal anti-D prophylaxis for rhesus-negative women who are pregnant.. BJOG, 111(9), 892-902.
• Karnon J, Peters J, Platt J, Chilcott J, McGoogan E & Brewer N (2004) Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis. HEALTH TECHNOL ASSES, 8(20), 1-+. View this article in WRRO
• Karnon J, Peters J, Platt J, Chilcott J, McGoogan E & Brewer N (2004) Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis.. Health Technol Assess, 8(20), iii-78.
• Holmes M, Chilcott J, Walters S, Whitby S & Akehurst R (2004) Economic evaluation of everolimus versus mycophenolate mofetil in combination with cyclosporine and prednisolone in de novo renal transplant recipients.. Transpl Int, 17(4), 182-187.
• Holmes M, Chilcott J, Walters S, Whitby S & Akehurst R (2004) Economic evaluation of everolimus versus mycophenolate mofetil in combination with cyclosporine and prednisolone in de novo renal transplant recipients. Transplant International, 17(4), 182-187.
• Czoski-Murray C, Warren E, Chilcott J, Beverley C, Psyllaki MA & Cowan J (2004) Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation.. Health Technol Assess, 8(13), iii-91.
• Czoski-Murray C, Warren E, Chilcott J, Beverley C, Psyllaki MA & Cowan J (2004) Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation. HEALTH TECHNOL ASSES, 8(13), 1-+. View this article in WRRO
• Kaltenthaler E, Vergel YB, Chilcott J, Thomas S, Blakeborough T, Walters SJ & Bouchier H (2004) A systematic review and economic evaluation of magnetic resonance cholangiopancreatography compared with diagnostic endoscopic retrograde cholangiopancreatography.. Health Technol Assess, 8(10), iii-89.
• Pandor A, Eastham J, Beverley C, Chilcott J & Paisley S (2004) Clinical effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: a systematic review.. Health Technol Assess, 8(12), iii-121.
• Karnon J, Peters J, Platt J, Chilcott J, McGoogan E & Brewer N (2004) Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis.. Health technology assessment (Winchester, England), 8(20).
• Kaltenthaler E, Vergel YB, Chilcott J, Thomas S, Blakeborough T, Walters SJ & Bouchier H (2004) A systematic review and economic evaluation of magnetic resonance cholangiopancreatography compared with diagnostic endoscopic retrograde cholangiopancreatography.. Health technology assessment (Winchester, England), 8(10). View this article in WRRO
• Pandor A, Eastham J, Beverley C, Chilcott J & Paisley S (2004) Clinical effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: a systematic review.. Health technology assessment (Winchester, England), 8(12).
• Tappenden P, Chilcott JB, Eggington S, Oakley J & McCabe C (2004) Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-beta and glatiramer acetate for multiple sclerosis.. Health technology assessment (Winchester, England), 8(27). View this article in WRRO
• Stevenson MD, Oakley J & Chilcott JB (2004) Gaussian process modeling in conjunction with individual patient simulation modeling: a case study describing the calculation of cost-effectiveness ratios for the treatment of established osteoporosis.. Med Decis Making, 24(1), 89-100.
• Karnon J, Brennan A & Chilcott J (2003) Commentary on Coyle et al., "The assessment of the economic return from controlled clinical trials".. Eur J Health Econ, 4(3), 239-240.
• Wight JP, Chilcott JB, Holmes MW & Brewer N (2003) Pulsatile machine perfusion vs. cold storage of kidneys for transplantation: a rapid and systematic review.. Clin Transplant, 17(4), 293-307.
• Chilcott J, McCabe C, Tappenden P, O'Hagan A, Cooper NJ, Abrams K, Claxton K, Miller DH & Cost Effectiveness of Multiple Sclerosis Therapies Study Group (2003) Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis.. BMJ, 326(7388), 522.
• Mar J, Rueda JR, Durán-Cantolla J, Schechter C & Chilcott J (2003) The cost-effectiveness of nCPAP treatment in patients with moderate-to-severe obstructive sleep apnoea.. Eur Respir J, 21(3), 515-522.
• Wight J, Chilcott J, Holmes M & Brewer N (2003) The clinical and cost-effectiveness of pulsatile machine perfusion versus cold storage of kidneys for transplantation retrieved from heart-beating and non-heart-beating donors.. Health technology assessment (Winchester, England), 7(25), 1-94.
• Wight J, Chilcott J, Holmes M & Brewer N (2003) The clinical and cost-effectiveness of pulsatile machine perfusion versus cold storage of kidneys for transplantation retrieved from heart-beating and non-heart-beating donors.. Health Technol Assess, 7(25), 1-94. View this article in WRRO
• Chilcott J, Brennan A, Booth A, Karnon J & Tappenden P (2003) The role of modelling in prioritising and planning clinical trials.. Health technology assessment (Winchester, England), 7(23). View this article in WRRO
• Chilcott J, Lloyd Jones M, Wight J, Forman K, Wray J, Beverley C & Tappenden P (2003) A review of the clinical effectiveness and cost-effectiveness of routine anti-D prophylaxis for pregnant women who are rhesus-negative.. Health Technol Assess, 7(4), iii-62. View this article in WRRO
• Walters SJ, Whitfield M, Akehurst RL & Chilcott JB (2003) Economic implications of the use of basiliximab in addition to triple immunosuppressive therapy in renal allograft recipients: a UK perspective.. Pharmacoeconomics, 21(2), 129-138.
• Chilcott JB, Holmes MW, Walters S, Akehurst RL & Nashan B (2002) The economics of basiliximab (Simulect) in preventing acute rejection in renal transplantation.. Transpl Int, 15(9-10), 486-493.
• Kaltenthaler E, Shackley P, Stevens K, Beverley C, Parry G & Chilcott J (2002) A systematic review and economic evaluation of computerised cognitive behaviour therapy for depression and anxiety. Health Technology Assessment, 6(22). View this article in WRRO
• Chilcott J, Tappenden P, Jones ML & Wight JP (2001) A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus.. Clin Ther, 23(11), 1792-1823.
• Walters SJ, Whitfield M, Akehurst RL & Chilcott JB (2001) Pharmacoeconomic evaluation of Simulect prophylaxis in renal transplant recipients.. Transplant Proc, 33(7-8), 3187-3191.
• Chilcott JB, Whitby SM & Moore R (2001) Clinical impact and health economic consequences of posttransplant type 2 diabetes mellitus.. Transplant Proc, 33(5A Suppl), 32S-39S.
• Cornell SJ, Chilcott JB & Brennan A (2001) Is it feasible to plan secondary care services for coronary heart disease rationally? A quantified modelling approach for a UK Health Authority.. J Epidemiol Community Health, 55(7), 521-527.
• Chilcott J, Wight J, Jones ML & Tappenden P (2001) The clinical effectiveness and cost-effectiveness of pioglitazone for type 2 diabetes mellitus: A rapid and systematic review. Health Technology Assessment, 5(19). View this article in WRRO
• Chilcott JB, Holmes M, Walters S & Akehurst RL (2001) Modeling long-term results of basiliximab (SIMULECT) use in patients after kidney transplantation in Great Britain. Przegla̧d lekarski, 58(2), 61-66.
• Chilcott JB, Holmes M, Walters S & Akehurst RL (2001) [Modeling long-term results of basiliximab (SIMULECT) use in patients after kidney transplantation in Great Britain].. Przegl Lek, 58(2), 61-66.
• Payne N, Chilcott J & McGoogan E (2000) Liquid-based cytology for cervical screening.. Cytopathology, 11(6), 469-470.
• Payne N, Chilcott J & McGoogan E (2000) Liquid-based cytology in cervical screening: A rapid and systematic review. Health Technology Assessment, 4(18). View this article in WRRO
• Akehurst R, Chilcott J & Holmes M (1999) The economic implications of the use of basiliximab versus placebo for the control of acute cellular rejection in renal allograft recipients.. TRANSPLANTATION, 67(7), S155-S155.
• CHILCOTT JB & CHRISTER AH (1991) MODELING OF CONDITION BASED MAINTENANCE AT THE COAL FACE. INT J PROD ECON, 22(1), 1-11.
• Cooper K, Nalbant G, Sutton A, Harnan S, Thokala P, Chilcott J, McNeill A & Bessey A () Systematic Review of Presymptomatic Treatment for Spinal Muscular Atrophy. International Journal of Neonatal Screening, 10(3), 56-56.
• Cooper K, Nalbant G, Sutton A, Harnan S, Thokala P, Chilcott J, McNeill A & Bessey A () Systematic Review of Newborn Screening Programmes for Spinal Muscular Atrophy. International Journal of Neonatal Screening, 10(3), 49-49.
• Chang J-YA, Chilcott JB & Latimer NR () Challenges and Opportunities in Interdisciplinary Research and Real-World Data for Treatment Sequences in Health Technology Assessments. PharmacoEconomics.
• Mahdi S, Buckland NJ & Chilcott J () Economic and health impacts of the Change4Life Food Scanner app: Findings from a randomized pilot and feasibility study. Frontiers in Nutrition, 10.
• Essat M, Cooper K, Bessey A, Clowes M, Chilcott JB & Hunter KD () Diagnostic accuracy of conventional oral examination for detecting oral cavity cancer and potentially malignant disorders in patients with clinically evident oral lesions: Systematic review and meta‐analysis. Head & Neck.
• Mahdi S, Buckland N & Chilcott J () Evaluating the Change4Life Food Scanner app: protocol for a randomised pilot and feasibility trial. Obesity Abstracts.
• Jones, R , Everson-Hock ES, Guillaume, L , Clapton, J , Goyder, E , Chilcott, J , Payne, N , Duenas, A , Sheppard, LM & Swann, C () The effectiveness of interventions aimed at improving access to health and mental health services for looked after children and young people: a systematic review.. Families, Relationships & Societies, 1(1), 71-85. View this article in WRRO
• Chilcott J, Jones ML & Wilkinson A () Docetaxel for the adjuvant treatment of early nodepositive breast cancer: a single technology appraisal. Health Technology Assessment, 13(Suppl 1), 7-13.
• Michaels J, Wilson E, Maheswaran R, Radley S, Jones G, Tong T-S, Kaltenthaler E, Aber A, Booth A, Buckley Woods H , Chilcott J et al () Configuration of vascular services: a multiple methods research programme. Programme Grants for Applied Research, 9(5), 1-150.

Chapters

• Payne N, Akehurst R, Beard S, Brennan A, Calvert N, Chilcott J, Mccabe C, Paisley S & Ward S (2017) Supporting purchasing in acute specialties in the trent region, Controlling Costs: Strategic Issues in Health Care Management (pp. 118-130).

Conference proceedings papers

• Mahdi S, Buckland N & Chilcott J (2020) STAKEHOLDER ENGAGEMENT FOR THE CONCEPTUAL MODELLING OF DIETARY DIGITAL INTERVENTIONS. MEDICAL DECISION MAKING, Vol. 40(5) (pp E458-E459)
• Amy J-YC, Latimer NR, Gillespie D & Chilcott J (2020) PREVALENCE, CHARACTERISTICS AND KEY ISSUES OF MODELLING TREATMENT SEQUENCES IN HEALTH ECONOMIC EVALUATIONS: A SYSTEMATIC REVIEW OF NICE TECHNOLOGY APPRAISALS. VALUE IN HEALTH, Vol. 23 (pp S606-S606)
• Xie J, Knoll S, Slowley A, Bensimon A, Vieira J, Chilcott J, Paisley S & Zhou Z (2018) Cost-Effectiveness of Ceritinib In Previously Untreated ALK-Positive Non-Small Cell Lung Cancer in the United Kingdom. Value in Health, Vol. 21 (pp S29-S29)
• Aber A, Tong T, Chilcott J, Maheswaran R, Thomas S, Nawaz S & Michaels J (2018) RISK ADJUSTMENT FOR COMORBIDITIES IN AORTIC ANEURYSM SURGERY. BRITISH JOURNAL OF SURGERY, Vol. 105 (pp 8-8)
• Bessey A, Leaviss J, de la Cruz GC, Chilcott J & Wong R (2017) THE COST-EFFECTIVENESS OF SCREENING FOR SEVERE COMBINED IMMUNODEFICIENCY (SCID) IN THE UK NHS NEWBORN BLOODSPOT SCREENING PROGRAMME. VALUE IN HEALTH, Vol. 20(9) (pp A501-A501)
• Paisley S, Seva J, Stevenson M, Archer R, Preston L, Chilcott J & Thornhill M (2016) Identifying Potential Early Biomarkers Of Acute Myocardial Infarction In The Biomedical Literature: A Comparison Of Text Mining And Manual Sifting Techniques. Value in Health, Vol. 19(7) (pp A367-A367)
• Kearns B, Chilcott & whyte (2016) Flexible parametric survival models and time-series analysis for extrapolating time-varying treatment effects in health technology assessment. Flexible parametric survival models and time-series analysis for extrapolating time-varying treatment effects in health technology assessment, 5 September 2016 - 8 September 2016.
• Thomas C, Watson P, Squires H, Chilcott J & Brennan A (2014) Validation of the SPHR Diabetes Prevention Model. Value in Health, Vol. 17(7) (pp A556-A556)
• Thomas C, Watson P, Greaves C, Squires H, Chilcott J & Brennan A (2014) Layering Interventions for Type-2 Diabetes Prevention Using The Sphr Diabetes Model. Value in Health, Vol. 17(7) (pp A347-A347)
• Bessey A, Chilcott J, Pandor A & Paisley S (2014) The Cost-Effectiveness of Expanding the Nhs Newborn Bloodspot Screening Programme To Include Homocystinuria (Hcu), Maple Syrup Urine Disease (Msud), Glutaric Aciduria Type 1 (Ga1), Isovaleric Acidaemia (Iva), and Long-Chain Hydroxyacyl-Coa Dehydrogenase Deficiency (Lchadd). Value in Health, Vol. 17(7) (pp A531-A531)
• Brereton L, Goyder E, Ingleton C, Gardiner C, Chilcott J, van der Wilt GJ, Oortwijn W, Mozygemba K, Lysdahl KB, Sacchini D & Lepper W (2014) Patient and public involvement in scope development for a palliative care health technology assessment in europe.. BMJ Support Palliat Care, Vol. 4 Suppl 1 (pp A40-A41). England View this article in WRRO
• Bessey A, Whyte S, Minton J & Chilcott J (2013) ECONOMIC EVALUATION OF AN ELECTRICAL IMPEDANCE SPECTROSCOPY (EIS) DEVICE USED AS AN ADJUNCT TO COLPOSCOPY. VALUE IN HEALTH, Vol. 16(7) (pp A407-A407)
• Tappenden P, Brennan A, Chilcott J & Squires H (2011) USING WHOLE DISEASE MODELLING TO INFORM ECONOMIC RECOMMENDATIONS FOR THE DETECTION, DIAGNOSIS, TREATMENT AND FOLLOW-UP OF COLORECTAL CANCER. VALUE IN HEALTH, Vol. 14(7) (pp A469-A470)
• Tappenden P, Brennan A, Chilcott J & Squires H (2011) A METHODOLOGICAL FRAMEWORK FOR DEVELOPING MODELS OF WHOLE DISEASE AREAS TO INFORM RESOURCE ALLOCATION DECISIONS. VALUE IN HEALTH, Vol. 14(7) (pp A243-A243)
• Payne N, Goyder E, Chilcott J, Sidwell A, Ram V, Buckley-Woods H, Guillaume L & Paisley S (2011) "SURELY THERE MUST BE MORE EVIDENCE ... !" REVIEWING LITERATURE TO SUPPORT THE DEVELOPMENT OF EVIDENCE-BASED PUBLIC HEALTH GUIDANCE BY THE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EFFECTIVENESS. J EPIDEMIOL COMMUN H, Vol. 65
• Duenas A, Tutuncu GY & Chilcott JB (2009) A genetic algorithm approach to the nurse scheduling problem with fuzzy preferences. IMA JOURNAL OF MANAGEMENT MATHEMATICS, Vol. 20(4) (pp 369-383)
• Mahdi S, Marr C, Buckland N & Chilcott J () Methods for the economic evaluation of obesity prevention dietary policies and population level interventions in children: a systematic review and critical appraisal of the evidence. Obesity Abstracts

Reports

• Chang J-YA, Chilcott JB & Latimer NR (2024) Leveraging real-world data to assess treatment sequences in health economic evaluations: a study protocol for emulating target trials using the English Cancer Registry and US Electronic Health Records-Derived Database View this article in WRRO
• Whyte S, Thomas C, Kearns B, Webster M & Chilcott J (2017) Optimising Bowel Cancer Screening Phase 1: Optimising the cost effectiveness of repeated FIT screening and screening strategies combining bowel scope and FIT screening View this article in WRRO

Posters

• Tappenden P, Brennan A, Chilcott J & Squires H Using Whole Disease Modelling to inform economic recommendations for the detection, diagnosis, treatment and followup of colorectal cancer.
• Chilcott J, Mildred M & Hummel S Use of the Metropolis-Hastings algorithm in the calibration of a patient level simulation of prostate cancer screening.

Other

• Pandor A, Eastham J, Beverley C, Chilcott J & Paisley S (2005) Clinical-effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: A systematic review. INT J TECHNOL ASSESS, 21(1), 150-150. View this article in WRRO

Preprints

• Cherodian R, Franklin M, Baxter S, Chilcott J & Gillespie D (2024) Smoking Cessation after Transitioning from Hospital to Community Stop Smoking Services: Insights from Real-world Data Analysis, Cold Spring Harbor Laboratory.
• Hock ES, Franklin M, Baxter S, Clowes M, Chilcott J & Gillespie D (2023) Covariates of success in quitting smoking: a systematic review of studies from 2008 to 2021 conducted to inform the statistical analyses of quitting outcomes of a hospital-based tobacco dependence treatment service in the United Kingdom. View this article in WRRO
• Hock ES, Franklin M, Baxter S, Clowes M, Chilcott J & Gillespie D (2023) Covariates of success in quitting smoking in the community and secondary acute or mental health care services: a rapid systematic review, Cold Spring Harbor Laboratory.
• Cooper K, Essat M, Clowes M, Chilcott J, Hunter K & Bessey A (2022) Diagnostic accuracy of biopsy versus full excision for diagnosis of oral cancer: A systematic review.